Tag Archives: VX-880

Lilly Initiates Additional Ph3 Orforglipron Trial; Mounjaro Label Update; Vertex, Amarin, and Intercept Q2 ‘23 Earnings; Glenmark Receives ANDA Approval for 2.5mg and 5mg Saxagliptin; Dario Introduces GLP-1RA Obesity Program; Tandem Initiates Sigi Patch Pump Trial

A series of cardiometabolic-related news items have been observed from Lilly, Vertex, Amarin, Intercept, Glenmark, Dario, and Tandem. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

ADA 2023 Key Press Releases (June 24)

On the second day of ADA 2023, ten cardiometabolic-related news items were observed from Lilly, Zealand, BI, Novo Nordisk, Biomea Fusion, Sciwind Biosciences, Medtronic, Vertex, and Esperion. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.
Register
Already a member? Log in here

Vertex Q1 ’23 Earnings; Lannett Restructures Debt and Files for Bankruptcy

Two cardiometabolic-related news items have been observed: Vertex hosted its Q1 ’23 earnings call (view press release; slides); and Lannett announced it has entered into a Restructuring Support Agreement (RSA) and plans to file voluntary petitions for reorganization pursuant to Chapter 11 of the US Bankruptcy Code in the US Bankruptcy Court for the District of Delaware (view press release). Below, FENIX provides highlights and insights into the respective news items. 

This content is for Read Less members only.
Register
Already a member? Log in here

Provention Bio to Resubmit Teplizumab BLA; Novo’s Wegovy Shortage Resolution Appears on Track; Vertex Q4 ’21 Earnings Update

Three cardiometabolic-related news items have been observed: Provention Bio announced plans to resubmit the teplizumab BLA following its Type B pre-BLA resubmission meeting with FDA; It has been reported that Novo’s Wegovy shortage may be resolved by H2 ’22 (view article); and Vertex hosted its Q4 ’21 earnings call (press release; slides). Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register
Already a member? Log in here